Data to guide the "test and treat era" of hepatitis C.

1. Falk GW, Buttar NS, Foster NR, et al. A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E2 in patients with Barrett’s esophagus. Gastroenterology 2012; 143:917–926. 2. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology 2011;140:1084– 1091. 3. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 2011;365:1375–1383. 4. Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology 2011;141:460–468. 5. Shirvani VN, Ouatu-Lascar R, Kaur BS, et al. Cyclooxygenase 2 expression in Barrett’s esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118:487–496. 6. Buttar NS, Wang KK, Leontovich O, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett’s esophagus. Gastroenterology 2002;122: 1101–1112. 7. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4: 431–436. 8. Heath EI, Canto MI, Piantadosi S, et al. Secondary chemoprevention of Barrett’s esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 2007;99:545–557.

[1]  H. Grabsch,et al.  Comparing virtual with conventional microscopy for the consensus diagnosis of Barrett’s neoplasia in the AspECT Barrett’s chemoprevention trial pathology audit , 2012, Histopathology.

[2]  M. Buti,et al.  Predicted effects of treatment for HCV infection vary among European countries. , 2012, Gastroenterology.

[3]  Michael J. O'Grady,et al.  Economic model of a birth cohort screening program for hepatitis C virus , 2012, Hepatology.

[4]  M. Golden,et al.  Cost-effectiveness and population outcomes of general population screening for hepatitis C. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  D. Owens,et al.  New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Author Names , 2012 .

[6]  D. Owens,et al.  New Protease Inhibitors for the Treatment of Chronic Hepatitis C , 2012, Annals of Internal Medicine.

[7]  J. Ward,et al.  The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C Antibody in U.S. Primary Care Settings , 2012, Annals of Internal Medicine.

[8]  R. Monina Klevens,et al.  The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007 , 2012, Annals of Internal Medicine.

[9]  T. Asselah,et al.  Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[10]  G. Barbarini,et al.  Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates). , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[11]  Hiroshi Mashimo,et al.  Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. , 2011, Gastroenterology.

[12]  Geoffrey Dusheiko,et al.  Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.

[13]  P. Belperio,et al.  A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  Angelique Zeringue,et al.  Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. , 2011, Gastroenterology.

[15]  Sprint Investigators,et al.  Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .

[16]  D. Rein,et al.  Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[17]  M. Manns,et al.  Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.

[18]  Peter J. Richardson,et al.  Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. , 2010, Gastroenterology.

[19]  Y. Kuo,et al.  Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[20]  H. M. Colvin,et al.  Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. , 2010 .

[21]  A. Bhattacharyya,et al.  Medication usage and the risk of neoplasia in patients with Barrett's esophagus. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  J. Jankowski,et al.  Chemoprevention of oesophageal cancer and the AspECT trial. , 2009, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[23]  A. Shar,et al.  Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. , 2007, Journal of the National Cancer Institute.

[24]  B. Bell,et al.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.

[25]  K. Subbaramaiah,et al.  Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. , 2003, Cancer cell.

[26]  Kenneth K Wang,et al.  Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. , 2002, Gastroenterology.

[27]  M. Omary,et al.  Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. , 2000, Gastroenterology.